Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance
Authors
Keywords
-
Journal
Nature Communications
Volume 8, Issue -, Pages 15617
Publisher
Springer Nature
Online
2017-06-08
DOI
10.1038/ncomms15617
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer
- (2016) F. J. Sanchez-Martin et al. CLINICAL CANCER RESEARCH
- MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations
- (2016) Sabrina Arena et al. Science Translational Medicine
- Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment
- (2015) M. P. Morelli et al. ANNALS OF ONCOLOGY
- Mapping the Pathways of Resistance to Targeted Therapies
- (2015) K. C. Wood CANCER RESEARCH
- Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance
- (2015) Willy Hugo et al. CELL
- Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer
- (2015) S. Arena et al. CLINICAL CANCER RESEARCH
- Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
- (2015) Giulia Siravegna et al. NATURE MEDICINE
- Targeting the translation machinery in cancer
- (2015) Mamatha Bhat et al. NATURE REVIEWS DRUG DISCOVERY
- Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers
- (2015) Sandra Misale et al. Nature Communications
- The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets
- (2015) Enzo Medico et al. Nature Communications
- Rare codons capacitate Kras-driven de novo tumorigenesis
- (2014) Nicole L.K. Pershing et al. JOURNAL OF CLINICAL INVESTIGATION
- eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies
- (2014) Lise Boussemart et al. NATURE
- Drugging the undruggable RAS: Mission Possible?
- (2014) Adrienne D. Cox et al. NATURE REVIEWS DRUG DISCOVERY
- RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis
- (2014) P. S. Winter et al. Science Signaling
- Systematic identification of signaling pathways with potential to confer anticancer drug resistance
- (2014) C. A. Martz et al. Science Signaling
- Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
- (2014) C. Bettegowda et al. Science Translational Medicine
- Resistance to Anti-EGFR Therapy in Colorectal Cancer: From Heterogeneity to Convergent Evolution
- (2014) S. Misale et al. Cancer Discovery
- KRAS and BRAF Mutations Predict Primary Resistance to Imatinib in Gastrointestinal Stromal Tumors
- (2012) C. Miranda et al. CLINICAL CANCER RESEARCH
- Rare Codons Regulate KRas Oncogenesis
- (2012) Benjamin L. Lampson et al. CURRENT BIOLOGY
- A public genome-scale lentiviral expression library of human ORFs
- (2011) Xiaoping Yang et al. NATURE METHODS
- PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis
- (2011) N. Ilic et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Amplification of the Driving Oncogene, KRAS or BRAF, Underpins Acquired Resistance to MEK1/2 Inhibitors in Colorectal Cancer Cells
- (2011) A. S. Little et al. Science Signaling
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
- (2011) L. V. Sequist et al. Science Translational Medicine
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
- (2010) Wendy De Roock et al. LANCET ONCOLOGY
- Allosteric modulation of Ras positions Q61 for a direct role in catalysis
- (2010) G. Buhrman et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
- (2009) F Loupakis et al. BRITISH JOURNAL OF CANCER
- Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology
- (2009) L. M. Ellis et al. CLINICAL CANCER RESEARCH
- SUnSET, a nonradioactive method to monitor protein synthesis
- (2009) Enrico K Schmidt et al. NATURE METHODS
- Acquired resistance to tyrosine kinase inhibitors during cancer therapy
- (2008) Jeffrey A Engelman et al. CURRENT OPINION IN GENETICS & DEVELOPMENT
- Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
- (2008) Rafael G. Amado et al. JOURNAL OF CLINICAL ONCOLOGY
- An activating KRAS mutation in imatinib-resistant chronic myeloid leukemia
- (2008) A Agarwal et al. LEUKEMIA
- EGFR Antagonists in Cancer Treatment
- (2008) Fortunato Ciardiello et al. NEW ENGLAND JOURNAL OF MEDICINE
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer
- (2008) Christos S. Karapetis et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started